CRISPR

AbbVie Terminates Collaboration and License Agreement with Caribou Biosciences
AbbVie Terminates Collaboration and License Agreement with Caribou Biosciences
Best Stocks
AbbVie
Caribou Biosciences
CRISPR
Flag link:
Why Shares of Tango Therapeutics Climbed This Week
Why Shares of Tango Therapeutics Climbed This Week
Motley Fool
Tango Therapeutics
CRISPR
gene editing
clinical trials
Flag link:
First-ever CRISPR-CAS9 therapy, exa-cel, shows promising results
First-ever CRISPR-CAS9 therapy, exa-cel, shows promising results
Clinical Trials Arena
Vertex Pharmaceuticals
exa-cel
CRISPR
beta thalassemia
Flag link:
This Scientist Is Building Custom Gene-Editing Tools—And Stands To Make Billions
This Scientist Is Building Custom Gene-Editing Tools—And Stands To Make Billions
Forbes
Scribe Therapeutics
CRISPR
gene editing
Benjamin Oakes
Flag link:
CRISPR on the Cusp: The Promise and the Pain Points
CRISPR on the Cusp: The Promise and the Pain Points
BioSpace
Intellia Therapeutics
HAE
NTLA-2002
CRISPR
Flag link:
Patients attack-free a year after receiving Intellia's hereditary angioedema CRISPR med
Patients attack-free a year after receiving Intellia's hereditary angioedema CRISPR med
Fierce Biotech
Intellia Therapeutics
HAE
hereditary angiodema
CRISPR
NTLA-2002
Flag link:
Landmark approval for Vertex's CRISPR drug 2 steps closer after trial wins, PDUFA date granted
Landmark approval for Vertex's CRISPR drug 2 steps closer after trial wins, PDUFA date granted
Fierce Biotech
Vertex Pharmaceuticals
CRISPR Therapeutics
CRISPR
gene editing
FDA
sickle cell disease
beta thalassemia
Flag link:
BIO: Caribou tries to 'go where the puck is going' by taking on cell therapy rivals on home ice
BIO: Caribou tries to 'go where the puck is going' by taking on cell therapy rivals on home ice
Fierce Biotech
BIO 2023
Caribou Biosciences
lymphoma
CRISPR
cell therapy
Flag link:
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
Fierce Biotech
Scribe Therapeutics
Eli Lilly
CRISPR
Prevail Therapeutics
gene therapy
biobucks
Jennifer Doudna
Flag link:
Function Oncology raises $28M to use CRISPR to tailor cancer diagnosis and treatment
Function Oncology raises $28M to use CRISPR to tailor cancer diagnosis and treatment
BioPharma Dive
Function Oncology
CRISPR
diagnostics
funding
cancer
Flag link:
Function Oncology raises $28M to use CRISPR to tailor cancer diagnosis and treatment
Function Oncology raises $28M to use CRISPR to tailor cancer diagnosis and treatment
Medtech Dive
Function Oncology
funding
CRISPR
diagnostics
Flag link:
Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality
Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality
Endpoints
Vertex Pharmaceuticals
diabetes
CRISPR
gene editing
CRISPR Therapeutics
Flag link:
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
Investors Business Daily
Intellia Therapeutics
CRISPR
FDA
Flag link:
Novartis Drops SCD Gene Therapy Program with Intellia
Novartis Drops SCD Gene Therapy Program with Intellia
BioSpace
Novartis
sickle cell disease
Intellia Therapeutics
CRISPR
gene editing
Flag link:
Vertex Teases Launch of Landmark CRISPR Therapy
Vertex Teases Launch of Landmark CRISPR Therapy
BioSpace
Vertex Pharmaceuticals
exa-cel
sickle cell disease
CRISPR
Flag link:
EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval
EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval
Fierce Biotech
Vertex Pharmaceuticals
CRISPR Therapeutics
EMA
CRISPR
sickle cell disease
exa-cel
Flag link:
Here Are the Top Five Biotech Trends for 2023
Here Are the Top Five Biotech Trends for 2023
NASDAQ
biotech
personalized medicine
bioprinting
tissue engineering
orphan drugs
drug discovery
gene editing
CRISPR
Flag link:
Editas halts lead CRISPR program after efficacy data underwhelm
Editas halts lead CRISPR program after efficacy data underwhelm
Endpoints
Editas Medicine
CRISPR
EDIT-101
clinical trials
Flag link:
Only Patient in N-of-1 CRISPR Trial for Duchenne Muscular Dystrophy Dies
Only Patient in N-of-1 CRISPR Trial for Duchenne Muscular Dystrophy Dies
BioSpace
CRISPR
clinical trials
patient deaths
Duchenne Muscular Dystrophy
CRD-TMH-001
Flag link:
Editas Rumored to be in “Advanced Discussions” around Potential Sale of Oncology Assets
Editas Rumored to be in “Advanced Discussions” around Potential Sale of Oncology Assets
BioSpace
Editas Medicine
gene editing
CRISPR
M&A
oncology
Flag link:

Pages